V
Overview
VIVIO Health uses patient-specific data to guide specialty drug decisions, focusing on real-world effectiveness at the individual level. Its product, VIVIO Precision Care, analyzes data to identify which high-cost therapies are likely to work and be cost-effective for a person. It replaces the pharma-centric model with a data-centric approach and aligns drug use with patient outcomes rather than policy. The goal is to improve patient outcomes while lowering total costs for self-insured employers, typically saving 25-35% of spend.
Work here?Claim your company
Simplify's take
What believers are saying
- The February 3, 2026 PBM reform law validates VIVIO’s transparency-first positioning.
- Managed Healthcare Executive quoted John in 2026, giving VIVIO credibility with benefits buyers.
- Employers facing specialty-drug inflation want alternatives that promise 25–35% spend reductions.
What critics are saying
- Vertically integrated PBMs can retaliate on network access, pricing, and employer contracting within 2026.
- The 2028 federal reporting regime commoditizes transparency, weakening VIVIO’s differentiation quickly.
- If savings claims fail to convert renewals, employers will replace VIVIO with incumbent PBMs.
What makes VIVIO Health unique
- VIVIO’s open-market PBM model bypasses rebates and formulary markups.
- Pramod John said on February 17, 2026, VIVIO already meets federal PBM transparency rules.
- VIVIO targets self-insured employers with data-driven specialty drug management and fiduciary reporting.
Help us improve and share your feedback! Did you find this helpful?